Johnson & Johnson (NYSE:JNJ) Shares Acquired by CFC Planning Co LLC

CFC Planning Co LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 30.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,354 shares of the company's stock after buying an additional 4,078 shares during the period. Johnson & Johnson comprises approximately 3.2% of CFC Planning Co LLC's investment portfolio, making the stock its 8th biggest holding. CFC Planning Co LLC's holdings in Johnson & Johnson were worth $2,878,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. MRP Capital Investments LLC raised its stake in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares in the last quarter. Syverson Strege & Co grew its holdings in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares during the last quarter. MBA Advisors LLC grew its holdings in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares during the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.82 during mid-day trading on Friday, hitting $156.87. The company's stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,066,975. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.15 and a beta of 0.41. The business's fifty day moving average is $153.75 and its two-hundred day moving average is $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.31%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a report on Thursday. Finally, Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.